Table 2.
Mean percentage (± standard error of the mean) chemokine positive cells relative to the CD4/CD8 ratios and CD14/CD19 ratios
| Group 1 (n = 15) | Group 2 (n = 16) | Group 3 (n = 16) | |
|---|---|---|---|
| CD4/CD8 ratio | 6·13 ± 0·86* | 2·21 ± 0·74* | 1·40 ± 0·05* |
| % IP-10+ cells | 1·72 ± 0·53 | 3·53 ± 1·11 | 2·90 ± 0·90 |
| % RANTES+ cells | 2·35 ± 1·55 | 2·10 ± 0·52 | 1·92 ± 0·53† |
| % MCP-1+ cells | 1·13 ± 0·33 | 0·93 ± 0·34‡ | 1·58 ± 0·59† |
| % MIP-1α+ cells | 6·03 ± 3·60 | 3·81 ± 1·14‡ | 8·19 ± 2·40† |
| CD14/CD19 ratio | 4·24 ± 1·33§ | 0·38 ± 0·06§ | 0·08 ± 0·01§ |
| % IP-10+ cells | 3·29 ± 1·05 | 2·76 ± 0·75 | 2·15 ± 0·85 |
| % RANTES+ cells | 1·39 ± 0·48 | 3·36 ± 1·56 | 1·64 ± 0·39 |
| % MCP-1+ cells | 1·41 ± 0·49 | 1·38 ± 0·46¶ | 0·84 ± 0·35 |
| % MIP-1α+ cells | 4·79 ± 1·63 | 5·37 ± 1·65¶ | 7·68 ± 3·67 |
*
CD4/CD8 ratio significantly reduced from group 1 to group 2 (P = 0·000) and group 2 to group 3 (P = 0·000)
†
MIP-1alpha+ cells increased in comparison with RANTES (P = 0·014) and MCP-1 (P = 0·012) positive cells in group 3
‡
MIP-1alpha+ cells increased compared with MCP-1+ cells in group 2 although not quite significant at the 0·02 level (P = 0·022)
§
CD4/CD19 ratio significantly reduced from group 1 to group 2 (P = 0·006) and group 2 to group 3 (P = 0·000)
¶
MIP-1alpha+ cells increased compared with MCP-1+ cells in group 2 (P = 0·026), although not significant at the 0·02 level.